Use of modified cells for the treatment of multiple sclerosis
AssigneeUniversitäT ZüRich
InventorsRoland MARTIN, Andreas LUTTEROTTI
Life of this patent
Estimating the term…
Abstract
The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
Claims21
1-20. (canceled)
A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell erythrocyte that is chemically coupled to a cocktail of peptides which cocktail comprises at least five peptides out of the following peptides:
- MBP13-32, MBP83-99, MBP111-129, MBP82-98, MBP82-99, MBP82-106, MBP87-106, MBP131-155, MBP146-170, PLP41-58, PLP89-106, PLP95-116, PLP139-154, PLP178-197, PLP190-209, MOG1-20, MOG11-30, MOG21-40, MOG35-55, MOG64-86.
A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell erythrocyte that is chemically coupled to a cocktail of peptides which cocktail comprises at least six peptides out of the following peptides:
- MBP13-32, MBP83-99, MBP111-129, MBP82-98, MBP82-99, MBP82-106, MBP87-106, MBP131-155, MBP146-170, PLP41-58, PLP89-106, PLP95-116, PLP139-154, PLP178-197, PLP190-209, MOG1-20, MOG11-30, MOG21-40, MOG35-55, MOG64-86.
A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell that is chemically coupled to a cocktail of peptides which cocktail comprises at least one of cocktails e-oo of tables 5.1-5.3.
Dependencies are inferred from the claim text.